title: Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance.
abstract: Increases in subclinical inflammation (C-reactive protein [CRP]) and impaired coagulation have been associated with increased obesity and insulin resistance. Only a few small studies have examined the effect of lifestyle changes, such as weight loss, increased physical activity, and insulin-sensitizing intervention on inflammation and coagulation. The Diabetes Prevention Program (DPP) clinical trial studied the effect of an intensive lifestyle intervention or metformin on progression to diabetes relative to placebo in 3,234 adults with impaired glucose tolerance. The effects of these interventions on CRP and fibrinogen at 12 months are examined in this report. Metformin reduced CRP in women compared with the placebo group. In men, the median changes in CRP from baseline to 1 year were -33% in the lifestyle group, -7% in the metformin group, and +5% in the placebo group. In women, the changes in CRP from baseline to follow-up were -29% in the lifestyle group, -14% in the metformin group, and 0% in the placebo group. In the lifestyle group weight loss rather than increased physical activity seems to account for most of the changes in CRP. Only modest reductions (although significant) were seen in fibrinogen levels in the lifestyle group relative to the metformin and placebo group. Lifestyle intervention reduced levels of nontraditional cardiovascular risk factors relative to both placebo and to a lesser degree to metformin.
authors.forename: Steven
authors.initials: S
authors.lastname: Haffner
authors.forename: Marinella
authors.initials: M
authors.lastname: Temprosa
authors.forename: Jill
authors.initials: J
authors.lastname: Crandall
authors.forename: Sarah
authors.initials: S
authors.lastname: Fowler
authors.forename: Ronald
authors.initials: R
authors.lastname: Goldberg
authors.forename: Edward
authors.initials: E
authors.lastname: Horton
authors.forename: Santica
authors.initials: S
authors.lastname: Marcovina
authors.forename: Kieren
authors.initials: K
authors.lastname: Mather
authors.forename: Trevor
authors.initials: T
authors.lastname: Orchard
authors.forename: Robert
authors.initials: R
authors.lastname: Ratner
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Barrett-Connor
mesh_terms: D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology*; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D003920:Diabetes Mellitus / Q000517:prevention & control; D005260:Female; D018149:Glucose Intolerance / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D007249:Inflammation / Q000517:prevention & control*; D008019:Life Style; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D009765:Obesity
chemical_list: D001786:Blood Glucose; D008687:Metformin